Lindley A Barbee1. 1. aDepartment of Medicine, Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA bPublic Health - Seattle & King County HIV/STD Program, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: The proportion of Neisseria gonorrhoeae isolates with reduced susceptibility to extended-spectrum cephalosporins (ESCs) has increased rapidly since 2006. Clinicians, researchers, and public health officials need to be prepared for the possibility of an era of untreatable gonorrhea. This review focuses on the evidence for current gonorrhea treatment recommendations, potential future treatment options, and other methods to control gonorrhea. RECENT FINDINGS: In addition to an increase in isolates with decreased susceptibility to ESCs, there have been reported treatment failures to both cefixime and ceftriaxone. In response, some countries have increased the recommended cephalosporin dose, and most now recommend dual therapy with an ESC and azithromycin. The pharynx has been implicated as a site for acquiring resistance through transformation with commensal Neisseria species or induced resistance through subtherapeutic antimicrobial levels. Thus, appropriate screening of the pharynx and treatment with a regimen that eradicates gonorrhea from the pharynx is necessary. At present, several studies are evaluating various novel treatment regimens in preparation for an era of untreatable gonorrhea. SUMMARY: Screening for asymptomatic infections, maintaining culture capacity to monitor antimicrobial resistance, treating with ceftriaxone and azithromycin, and ensuring that all sexual partners are treated are among the best strategies to control gonorrhea in the current clime.
PURPOSE OF REVIEW: The proportion of Neisseria gonorrhoeae isolates with reduced susceptibility to extended-spectrum cephalosporins (ESCs) has increased rapidly since 2006. Clinicians, researchers, and public health officials need to be prepared for the possibility of an era of untreatable gonorrhea. This review focuses on the evidence for current gonorrhea treatment recommendations, potential future treatment options, and other methods to control gonorrhea. RECENT FINDINGS: In addition to an increase in isolates with decreased susceptibility to ESCs, there have been reported treatment failures to both cefixime and ceftriaxone. In response, some countries have increased the recommended cephalosporin dose, and most now recommend dual therapy with an ESC and azithromycin. The pharynx has been implicated as a site for acquiring resistance through transformation with commensal Neisseria species or induced resistance through subtherapeutic antimicrobial levels. Thus, appropriate screening of the pharynx and treatment with a regimen that eradicates gonorrhea from the pharynx is necessary. At present, several studies are evaluating various novel treatment regimens in preparation for an era of untreatable gonorrhea. SUMMARY: Screening for asymptomatic infections, maintaining culture capacity to monitor antimicrobial resistance, treating with ceftriaxone and azithromycin, and ensuring that all sexual partners are treated are among the best strategies to control gonorrhea in the current clime.
Authors: Vanessa G Allen; Leo Mitterni; Christine Seah; Anuradha Rebbapragada; Irene E Martin; Colin Lee; Heather Siebert; Lynn Towns; Roberto G Melano; Donald E Low Journal: JAMA Date: 2013-01-09 Impact factor: 56.272
Authors: H W Jaffe; A L Schroeter; G H Reynolds; A A Zaidi; J E Martin; J D Thayer Journal: Antimicrob Agents Chemother Date: 1979-04 Impact factor: 5.191
Authors: David F Bruhn; Samanthi L Waidyarachchi; Dora B Madhura; Dimitri Shcherbakov; Zhong Zheng; Jiuyu Liu; Yasser M Abdelrahman; Aman P Singh; Stefan Duscha; Chetan Rathi; Robin B Lee; Robert J Belland; Bernd Meibohm; Jason W Rosch; Erik C Böttger; Richard E Lee Journal: Sci Transl Med Date: 2015-05-20 Impact factor: 17.956
Authors: Eliza Thapa; Hanna M Knauss; Benjamin A Colvin; Benjamin A Fischer; Nathan J Weyand Journal: Antimicrob Agents Chemother Date: 2020-07-22 Impact factor: 5.191
Authors: David W Eyre; Dilrini De Silva; Kevin Cole; Joanna Peters; Michelle J Cole; Yonatan H Grad; Walter Demczuk; Irene Martin; Michael R Mulvey; Derrick W Crook; A Sarah Walker; Tim E A Peto; John Paul Journal: J Antimicrob Chemother Date: 2017-07-01 Impact factor: 5.790
Authors: Jonathan D Lenz; Elizabeth A Stohl; Rosanna M Robertson; Kathleen T Hackett; Kathryn Fisher; Kalia Xiong; Mijoon Lee; Dusan Hesek; Shahriar Mobashery; H Steven Seifert; Christopher Davies; Joseph P Dillard Journal: J Biol Chem Date: 2016-03-16 Impact factor: 5.157
Authors: Lindley A Barbee; Olusegun O Soge; David A Katz; Julia C Dombrowski; King K Holmes; Matthew R Golden Journal: Clin Infect Dis Date: 2018-02-10 Impact factor: 9.079
Authors: Jonathan D Lenz; Kristina A Shirk; Adrienne Jolicoeur; Joseph P Dillard Journal: Antimicrob Agents Chemother Date: 2018-11-26 Impact factor: 5.191